A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.

Phase 1 Completed 30 enrolled AstraZeneca Parexel · collab

RandomizedSequentialDouble-blindTreatment

Summary

This is a Phase 1 study to assess the the safety, tolerability and pharmacokinetics (PK) of AZD2373, following subcutaneous (SC) administration of single ascending doses (SAD) of AZD2373 in healthy male subjects of African ancestry.

Timeline

Start: 2020-02-13
Primary completion: 2021-08-31
Completion: 2021-08-31

Publications

Bruggeman LA, Sedor JR, O'Toole JF. Apolipoprotein L1 and mechanisms of kidney disease susceptibility. Curr Opin Nephrol Hypertens. 2021 May 1;30(3):317-323. doi: 10.1097/MNH.0000000000000704.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Opemalirsen	Unknown	—	Subcutaneous

Indications

No indication recorded.